I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...

Luckily for investors, CSL’s core plasma business Behring came to the rescue with ... Idelvion is an albumin fusion protein cited as the new standard-of-care for haemophilia B.

CSL Behring also joined the fight against the coronavirus pandemic this month when its Australian unit started working on a plasma-based therapy for patients with severe forms of COVID-19.

CSL reported a 10% lift in Behring division revenue to US$5.74 billion. This reflected a 15% jump in immunoglobulin product ...

CSL reported a 10% lift in Behring division revenue to US$5.74 billion. This reflected a 15% jump in immunoglobulin product sales to US$3,174 million, a 9% increase in Albumin sales to US$672 ...